| Document |
Document Title |
|
WO/2016/164501A1 |
In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type ...
|
|
WO/2016/164497A1 |
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4: ActRIIB complexes...
|
|
WO/2016/161343A2 |
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...
|
|
WO/2016/157130A1 |
Macroalgae compositions, processes for the preparation thereof, and applications thereof as a sports nutrition supplement are described. More particularly, a macroalgae composition includes a macroalgae extract including medium chain and...
|
|
WO/2016/158810A1 |
This agent for the prevention and/or treatment of conditions associated with RAGE/ligand interactions, containing as an active ingredient a compound represented by formula (I): (in the formula, each of the symbols is defined as in the de...
|
|
WO/2016/155661A1 |
Provided is a compound capable of being used to treat diseases caused by cell proliferation and/or angiogenesis or diseases associated with or accompanied by the cell proliferation and/or the angiogenesis.
|
|
WO/2016/155358A1 |
Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF proline h...
|
|
WO/2016/161294A1 |
Provided herein are methods and kits for increasing cardiac contraction, increasing mitochondrial activity, and/or increasing oxphos activity. Such methods include use of therapeutically effective amounts of one or more agents that incre...
|
|
WO/2016/156470A1 |
The present invention relates to formulations containing ultra-deformable drug-free particles and their use in treating soft-tissue soreness, such as delayed onset muscle soreness (DOMS) and exercise-induced muscle soreness. The formulat...
|
|
WO/2016/152519A1 |
Provided is an external medicine for diffuse plexiform neurofibroma. The external medicine for diffuse plexiform neurofibroma according to the present invention comprises as an active ingredient at least one member selected from the grou...
|
|
WO/2016/149092A1 |
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...
|
|
WO/2016/148213A1 |
Disclosed are: any one polypeptide selected from (a) a polypeptide which comprises the amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide which comprises an amino acid sequence produced by deleting, substituting, insertin...
|
|
WO/2016/145935A1 |
Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. ...
|
|
WO/2016/144936A1 |
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...
|
|
WO/2016/140922A1 |
The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject inventi...
|
|
WO/2016/138387A1 |
The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleo...
|
|
WO/2016/135308A1 |
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for the preparation thereof. Also described are a compound of the formula (A), a ...
|
|
WO/2016/135262A1 |
The invention relates to the field of medicine and particularly to the use of amino-C2-C6-alkyl nitrates or amino-C2-C4-alkyl nitrates or the pharmaceutically acceptable salt thereof for the treatment and prophylaxis of a chronic disease...
|
|
WO/2016/137963A1 |
Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include a...
|
|
WO/2016/136933A1 |
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...
|
|
WO/2016/135644A1 |
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
|
|
WO/2016/133838A1 |
Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvat...
|
|
WO/2016/128358A1 |
Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of...
|
|
WO/2016/128772A1 |
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.
|
|
WO/2016/129140A1 |
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...
|
|
WO/2016/124922A1 |
A composition comprising CRH, CRH binding protein (CRH-BP), alpha-2 macroglobulin (A2M) and alpha-melanocyte stimulating hormone (alpha-MSH) for use in treatment of a medical condition selected from the list consisting of an ulcer or sof...
|
|
WO/2016/127135A1 |
Disclosed herein are compounds that are effective for treatment of various disease states. Dosing includes both single administration and regimens of cycling dosages.
|
|
WO/2016/125025A1 |
A composition for improving muscle metabolism in a subject and methods for manufacturing and using same. Embodiments include compositions having an extract of Rhaponticum and an extract of Rhodiola. An extract of Rhaponticum may include ...
|
|
WO/2016/121923A1 |
The present invention pertains to a muscle synthesis promoter which exhibits a muscle synthesis promotion action, and with which it is possible to efficiently ingest milk protein. More specifically, the present invention pertains to a mu...
|
|
WO/2016/120652A1 |
PPARγ controls the expression of the TGFβ family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation. Thus, GDF3 as a secreted extrinsic effector protei...
|
|
WO/2016/114322A1 |
The present invention provides an agent for the prevention and/or treatment of amyotrophic lateral sclerosis (ALS), the agent containing: one or more kinase inhibitors selected from the group consisting of epidermal growth factor recepto...
|
|
WO/2016/112497A1 |
Provided are a human anti-human interferon alpha (IFNα) antibody and coding gene and application thereof. By combining a gene engineering method with a bacteriophage surface display technology, a plurality of subtype anti-human IFNα ge...
|
|
WO/2016/111347A1 |
Provided is a drug the active ingredient of which is a compound having antagonistic activity against EP4 receptor in the prevention and/or treatment of disease attributed to activation of EP4 receptor. The compound represented by general...
|
|
WO/2016/111357A1 |
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-
tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...
|
|
WO/2016/108288A1 |
A method for producing skeletal muscle progenitor cells from pluripotent stem cells, said method comprising the following steps (1) and (2A) or (2B):(1) a step for culturing the pluripotent stem cells in a liquid culture medium containin...
|
|
WO/2016/106626A1 |
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...
|
|
WO/2016/106625A1 |
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...
|
|
WO/2016/098061A1 |
Described herein are methods of treating and preventing muscle wasting and muscle loss, using adherent stromal cells and conditioned medium produced thereby.
|
|
WO/2016/097299A1 |
Compound for treatment of myotonic dystrophy type The present invention relates to a compound, or a salt thereof, and a pharmaceutical composition comprising said compound, or a salt thereof, for use in the prevention and/or treatment of...
|
|
WO/2016/092439A1 |
The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagon...
|
|
WO/2016/092139A1 |
The invention relates to a drug that permits the effective treatment of motor neurone diseases. In particular, the invention relates to a composition comprising a) a compound or any of the pharmaceutically acceptable salts thereof, where...
|
|
WO/2016/088797A1 |
Provided are: a nucleic acid that reduces toxicity caused by abnormal accumulation of an RNA-binding protein in cells and is usable for preventing or treating a neurodegenerative disease; and a prophylactic or therapeutic agent for a neu...
|
|
WO/2016/089304A1 |
The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivati...
|
|
WO/2016/086103A1 |
The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibros...
|
|
WO/2016/086114A1 |
The present invention relates to methods and sports drink compositions for treating and/or preventing muscle weakness and/or increasing muscle strength and/or stamina in subjects in need thereof. The sports drink composition includes meg...
|
|
WO/2016/086136A1 |
The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such a...
|
|
WO/2016/084816A1 |
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...
|
|
WO/2016/084870A1 |
Provided is an acylaminophenyl-group-containing compound having a neuroprotective effect. Also provided is a neuroprotective agent including an acylaminophenyl-group-containing compound. A novel acylaminophenyl-group-containing compound,...
|
|
WO/2016/084412A1 |
It is found that the activation of a B cell can be inhibited by TGF-beta3 produced by LAG3+ Treg. A B cell activation inhibitor comprising TGF-beta3 or a molecule having the function of TGF-beta3 and a therapeutic agent for autoimmune di...
|
|
WO/2016/080887A1 |
The present invention relates to FHLl (Four-and-a-half-LIM domain 1) as a new muscle specific autoantigen. The invention provides methods for diagnosis of autoimmune muscle diseases, such as myositis, polymyositis, deimatomyositis, inclu...
|
